1h Free Analyst Time
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2018Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) pipeline Target constitutes close to 30 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Lysine Specific Histone Demethylase 1A - Pipeline Review, H2 2018, outlays comprehensive information on the Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Lysine-specific histone demethylase 1A (KDM1A) also known as lysine (K)-specific demethylase 1A (LSD1) is a protein in encoded by the KDM1A gene. LSD1 specifically demethylates mono- or dimethylated dimethylated histone H3 lysine4 (H3K4) and H3 lysine 9 (H3K9) via a redox process. LSD1 played an important role in a broad spectrum of biological processes, including cell proliferation, adipogenesis, spermatogenesis, chromosome segregation and embryonic development.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 4 molecules, respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Central Nervous System, Other Diseases, Immunology, Infectious Disease and Metabolic Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Small-Cell Lung Cancer, Ewing Sarcoma, Myelodysplastic Syndrome, Sickle Cell Disease, Alzheimer's Disease, Breast Cancer, Melanoma, Orphan Diseases (Rare Diseases), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Promyelocytic Leukemia, Autoimmune Disorders, Dementia, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Follicular Lymphoma, Gastric Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Huntington Disease, Leukemias, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Myelofibrosis, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, Obesity, Ovarian Cancer, Parkinson's Disease, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Psychosis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Solid Tumor, Type 2 Diabetes and Viral Infections.
Furthermore, this report also reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)
- The report reviews Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Overview
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Companies Involved in Therapeutics Development
4SC AG
Beactica AB
Celgene Corp
Constellation Pharmaceuticals Inc
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Imago BioSciences Inc
Incyte Corp
Mirati Therapeutics Inc
Oryzon Genomics SA
Takeda Pharmaceutical Co Ltd
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit KDM1A and PRKCQ for Metastatic Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2879552 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-97211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iadademstat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMG-7289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-59872 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORY-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RASP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit KDM1A for Acute Myelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit KDM1A for Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit KDM1A for Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LSD1 for Small Cell Lung Cancer and Acute Myelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KDM1A for Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KDM1A for Gastric Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LSD-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LSD1 for Alzheimer's Disease, Oncology and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LSD1 for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LSD1 for Obesity, Type 2 Diabetes and Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LSD1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-2509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-2577 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit KDM1A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3775440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-418 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vafidemstat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Dormant Products
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Discontinued Products
Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Product Development Milestones
Featured News & Press Releases
Sep 10, 2018: ORYZON receives approval to start ALICE: a Phase II a clinical trial in AML with Iadademstat (ORY-1001)
Sep 07, 2018: Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
Aug 22, 2018: Imago BioSciences completes enrolment in Phase l/lla trial of IMG-7289
Jul 31, 2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma
Jul 03, 2018: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma
Jun 25, 2018: ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
Jun 01, 2018: Oryzon to present at upcoming several international conferences
May 30, 2018: Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day
May 29, 2018: ORYZON Receives Approval in the United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
May 14, 2018: ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
May 08, 2018: ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY- 2001
Apr 27, 2018: Oryzon Genomics to present at upcoming international conferences
Apr 09, 2018: Oryzon Genomics to present at upcoming conferences
Apr 04, 2018: ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
Mar 05, 2018: ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 4SC AG, H2 2018
Pipeline by Beactica AB, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Constellation Pharmaceuticals Inc, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Pipeline by Imago BioSciences Inc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Mirati Therapeutics Inc, H2 2018
Pipeline by Oryzon Genomics SA, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- Beactica AB
- Celgene Corp
- Constellation Pharmaceuticals Inc
- GlaxoSmithKline Plc
- Hanmi Pharmaceuticals Co Ltd
- Imago BioSciences Inc
- Incyte Corp
- Mirati Therapeutics Inc
- Oryzon Genomics SA
- Takeda Pharmaceutical Co Ltd
